124 related articles for article (PubMed ID: 17312396)
1. N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation.
Park DM; Li J; Okamoto H; Akeju O; Kim SH; Lubensky I; Vortmeyer A; Dambrosia J; Weil RJ; Oldfield EH; Park JK; Zhuang Z
Cell Cycle; 2007 Feb; 6(4):467-70. PubMed ID: 17312396
[TBL] [Abstract][Full Text] [Related]
2. The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma.
Lu J; Zhuang Z; Song DK; Mehta GU; Ikejiri B; Mushlin H; Park DM; Lonser RR
J Neurosurg; 2010 Aug; 113(2):225-33. PubMed ID: 20001590
[TBL] [Abstract][Full Text] [Related]
3. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
4. N-CoR controls differentiation of neural stem cells into astrocytes.
Hermanson O; Jepsen K; Rosenfeld MG
Nature; 2002 Oct; 419(6910):934-9. PubMed ID: 12410313
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
6. The nuclear receptor corepressor N-CoR regulates differentiation: N-CoR directly interacts with MyoD.
Bailey P; Downes M; Lau P; Harris J; Chen SL; Hamamori Y; Sartorelli V; Muscat GE
Mol Endocrinol; 1999 Jul; 13(7):1155-68. PubMed ID: 10406466
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of nuclear receptor corepressor misfolding in acute promyelocytic leukemia cells with genistein.
Ng AP; Nin DS; Fong JH; Venkataraman D; Chen CS; Khan M
Mol Cancer Ther; 2007 Aug; 6(8):2240-8. PubMed ID: 17699721
[TBL] [Abstract][Full Text] [Related]
8. Discovery of LAMP-2A as potential biomarkers for glioblastoma development by modulating apoptosis through N-CoR degradation.
Wang Y; Zhang B; Wang J; Wu H; Xu S; Zhang J; Wang L
Cell Commun Signal; 2021 Mar; 19(1):40. PubMed ID: 33761934
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
[TBL] [Abstract][Full Text] [Related]
10. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
11. Girdin maintains the stemness of glioblastoma stem cells.
Natsume A; Kato T; Kinjo S; Enomoto A; Toda H; Shimato S; Ohka F; Motomura K; Kondo Y; Miyata T; Takahashi M; Wakabayashi T
Oncogene; 2012 May; 31(22):2715-24. PubMed ID: 22020337
[TBL] [Abstract][Full Text] [Related]
12. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
[TBL] [Abstract][Full Text] [Related]
13. Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells.
Racanicchi S; Maccherani C; Liberatore C; Billi M; Gelmetti V; Panigada M; Rizzo G; Nervi C; Grignani F
EMBO J; 2005 Mar; 24(6):1232-42. PubMed ID: 15729358
[TBL] [Abstract][Full Text] [Related]
14. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells.
Spina R; Voss DM; Asnaghi L; Sloan A; Bar EE
Oncotarget; 2016 Jan; 7(1):459-72. PubMed ID: 26575950
[TBL] [Abstract][Full Text] [Related]
15. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
Marisetty AL; Lu L; Veo BL; Liu B; Coarfa C; Kamal MM; Kassem DH; Irshad K; Lu Y; Gumin J; Henry V; Paulucci-Holthauzen A; Rao G; Baladandayuthapani V; Lang FF; Fuller GN; Majumder S
Neuro Oncol; 2019 Jun; 21(6):775-785. PubMed ID: 30953587
[TBL] [Abstract][Full Text] [Related]
16. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y
Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665
[TBL] [Abstract][Full Text] [Related]
17. The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets.
Cenciarelli C; Marei HE; Zonfrillo M; Casalbore P; Felsani A; Giannetti S; Trevisi G; Althani A; Mangiola A
Oncotarget; 2017 Mar; 8(11):17873-17886. PubMed ID: 28157712
[TBL] [Abstract][Full Text] [Related]
18. Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Daniele S; Zappelli E; Natali L; Martini C; Trincavelli ML
Cell Death Dis; 2014 Nov; 5(11):e1539. PubMed ID: 25429616
[TBL] [Abstract][Full Text] [Related]
19. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
20. The nuclear receptor corepressor (N-CoR) modulates basal and activated transcription of genes controlled by retinoic acid.
Loinder K; Söderström M
J Steroid Biochem Mol Biol; 2003 Jan; 84(1):15-21. PubMed ID: 12648520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
